Search 

Edinburgh BioQuarter is the commercialisation arm of the University of Edinburgh Medical School and Veterinary College. We have recently spun out several companies in the devices, informatics and CRO space. Current companies in incubation include:

• FibromEd, which is developing improved hepatocyte products for drug toxicity testing
• Asclepius, an orphan drug company focused on rare renal disease
• Edinburgh Molecular Imaging, a new imaging technology focused on rapid diagnosis of lung pathology including fibrosis
• Therapivo, a new approach to the treatment of metastatic cancer based on phenotypic drug development
• Vaccine company which is utilising novel adjuvant technology
• Anti-infective company with broad spectrum anti-viral technolgy focused on respiratory infections  

Ennar Pharma was founded in July 2010 to develop a better and safer topical treatment for mild-to-moderate psoriasis. Patents, protecting the technology, have been granted in Europe and the USA. The company is financially supported by an investment by EVA- a Basel based venture capital company- and uses a network of strategic partners to develop the production of EGF and develop a suitable cream-based pharmaceutical product. Producers for the cGMP production of high-quality EGF(epidermal growth factor) and for a stable cream formulation of the active ingredient have been contracted and a Proof-of-Concept trial is running at the Dermatology Clinic of the University of Zurich. The trial, which is carried out with mild-to-moderate psoriasis patients, aims to establish the validity of the mode-of-action proposed for the EGF-based topical formulation and test an optimised formulation for clinical efficacy and safety. Results of the trial are expected in Q1 2013.

Enterome is developing diagnostic products based on metagenomics of the human intestinal microbiota in patients with metabolic and inflammatory bowel diseases.

EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.

EpiTherapeutics' development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. Subsequent developments may identify other potential clinical indications outside oncology.

In December 2010, Epitherapeutics signed a drug discovery collaboration with Abbott Laboratories.

Epitherapeutics employs 25 FTE and is headquartered in Copenhagen.

Founded in 2008, Excellentia  Global Partners serves companies worldwide in their quest to raise capital.  Typical companies have initial proof of concept, have not raised professional capital to date, and are willing to engage a professional and highly regarded investment banker.  EGP is based in New York City, and has worked with companies in the U.S., Asia and Europe.  

Genticel is a clinical stage biopharmaceutical company that develops multivalent vaccines for patients infected with Human Papillomavirus (HPV). Till date, the company has raised EUR 27 Mio in funding.

Current investors include Edmond de Rothschild Venture Partners, Innobio Fund, IDInvest (Allianz) and Amundi. 

Our lead investigational vaccine, ProCervix, has successfully finished a very positive data-rich Phase Ib trial on 47 HPV16 and/or 18 infected women. ProCervix is the first therapeutic vaccine offering a solution to the more than 93 million women worldwide already infected with HPV 16 and/or 18 before the appearance of high grade neoplasia. This very large population, exposed at high risk to develop cervical cancer, is only now becoming accessible thanks to new screening guidelines prescribing first line HPV-based testing.

A large survey of prescribers and a Market Access Study predict overwhelming acceptability and a very large market potential.

Genticel wants to take ProCervix into Clinical Phase II and further develop our second product, a heptavalent therapeutic HPV vaccine, up to clinical stage.

To do this, we intend to raise additional capital from our current and selected international investors.